SCHEMBL17899873

SCHEMBL17899873

CC(C)(Oc1ccc2ccccc2c1-c1ccc(C#N)c2ccccc12)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SLC22A12 Q96S37 16/20 1.00
▸ KDM4E B2RXH2 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ PPARG P37231 1/20 0.44
▸ PPARD Q03181 1/20 0.44
▸ PPARA Q07869 1/20 0.44
▸ SLC22A6 Q4U2R8 1/20 0.43
▸ SLC22A11 Q9NSA0 1/20 0.43
▸ IMPDH2 P12268 1/20 0.42
▸ IMPDH1 P20839 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17899864 0.86 SLC22A12 (0.75) SLC22A12KDM4EALDH1A1HSD17B10PPARA
SCHEMBL19435574 0.79 IMPDH2 (0.64) SLC22A12KDM4EALDH1A1IMPDH2IMPDH1
SCHEMBL17899890 0.77 SLC22A12 (1.00) SLC22A12SLC22A6SLC22A11
SCHEMBL19547904 0.75 SLC22A12 (0.60) SLC22A12IMPDH2IMPDH1
SCHEMBL19435545 0.72 SLC22A12 (0.57) SLC22A12KDM4EALDH1A1IMPDH2IMPDH1
SCHEMBL19435497 0.71 SLC22A12 (0.54) SLC22A12KDM4EALDH1A1HSD17B10CYP2C9
SCHEMBL5822854 0.71 ALDH1A1 (1.00) SLC22A12KDM4EALDH1A1HSD17B10CYP2C9
SCHEMBL17899836 0.71 SLC22A12 (0.55) SLC22A12KDM4EALDH1A1HSD17B10CYP2C9
SCHEMBL28388162 0.70 SLC22A12 (0.54) SLC22A12KDM4EALDH1A1HSD17B10CYP2C9
SCHEMBL17899889 0.70 SLC22A12 (0.74) SLC22A12KDM4ESLC22A6SLC22A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 — — EP claimed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 — — US claimed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 — — EP claimed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 — — US claimed
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 — — EP disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 — — US disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 — — US disclosed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 — — EP disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 — — US disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 — — US disclosed
WO-2016108282-A1 URAT1 INHIBITOR 日本ケミファ株式会社 2016-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290795-A1 URAT1 INHIBITOR SLC10A1, XDH, URB2 SLC22A12 512/4885KDM4E 2799/4885ALDH1A1 673/4885
US-10173990-B2 URAT1 inhibitor SLC10A1, XDH, URB2 SLC22A12 500/4885KDM4E 2791/4885ALDH1A1 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback